About this document
Cost-Effectiveness of Aerobika® in COPD by japanprotonvpn is a document available to read on EtoBox.
This study evaluates the cost-effectiveness of the Aerobika oscillating positive expiratory pressure device for managing chronic obstructive pulmonary disease (COPD) exacerbations in Canada. The analysis indicates that using the Aerobika device saves $694 in healthcare costs and yields an additional 0.04 quality-adjusted life years (QALYs) compared to no therapy, making it a dominant and cost-effective treatment option. The findings support the integration of the Aerobika device into COPD management strateg
- Author
- japanprotonvpn
- Language
- EN